Ubs Group Ag Pyxis Oncology, Inc. Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 396,096 shares of PYXS stock, worth $1.34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

396,096

Previous 396,844 0.19%

Holding current value

$1.34 Million

Previous $388,000 12.11%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$0.88 - $1.35 $658 - $1,009	-748 Reduced 0.19%	396,096 $435,000
Q1 2025 May 13, 2025	SELL	$0.98 - $1.76 $48,857 - $87,744	-49,855 Reduced 11.16%	396,844 $388,000
Q4 2024 Feb 14, 2025	BUY	$1.54 - $4.77 $644,639 - $2 Million	418,597 Added 1489.56%	446,699 $692,000
Q3 2024 Nov 14, 2024	BUY	$2.83 - $3.94 $29,499 - $41,070	10,424 Added 58.97%	28,102 $103,000
Q2 2024 Aug 13, 2024	SELL	$3.06 - $5.58 $32,350 - $58,991	-10,572 Reduced 37.42%	17,678 $58,000
Q1 2024 May 13, 2024	BUY	$2.03 - $6.59 $51,348 - $166,694	25,295 Added 856.01%	28,250 $120,000
Q3 2023 Nov 09, 2023	SELL	$1.6 - $2.78 $7,512 - $13,052	-4,695 Reduced 61.37%	2,955 $5,000
Q2 2023 Aug 11, 2023	BUY	$2.46 - $4.07 $11,549 - $19,108	4,695 Added 158.88%	7,650 $19,000
Q1 2023 May 12, 2023	BUY	$1.38 - $6.0 $4,077 - $17,730	2,955 New	2,955 $11,000
Q3 2022 Nov 10, 2022	SELL	$1.88 - $3.03 $398 - $642	-212 Reduced 57.77%	155 $0
Q2 2022 Aug 10, 2022	SELL	$2.02 - $4.53 $2,151 - $4,824	-1,065 Reduced 74.37%	367 $1,000
Q1 2022 May 16, 2022	SELL	$4.04 - $11.43 $13,679 - $38,701	-3,386 Reduced 70.28%	1,432 $6,000
Q4 2021 Feb 14, 2022	BUY	$8.39 - $13.64 $40,423 - $65,717	4,818 New	4,818 $53,000

Others Institutions Holding PYXS

# of Institutions

Shares Held

22.9M

Call Options Held

Put Options Held

View Full List

About Pyxis Oncology, Inc.

Ticker PYXS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,096,400
Market Cap $119M
Description
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...

More about PYXS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account